Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Baltics leading pharmaceutical company Grindeks expands to new export markets worldwide
Tuesday, February 18, 2025The leading pharmaceutical company in the Baltics Grindeks continues to strengthen its global presence by entering new export markets This year for the first time Grindeks products will be delivered to Panama The companys export markets already inclu...
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
Saturday, February 15, 2025Global biotechnology leader CSL and samRNA pioneer Arcturus Therapeutics Nasdaq ARCT today announced that the European Commission has granted marketing authorization for KOSTAIVE ARCT a selfamplifying mRNA COVID vaccine
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
Friday, February 14, 2025Galderma announced that the European Commission has approved Nemluvio for both moderatetosevere atopic dermatitis and prurigo nodularis in the European Union EU Nemluvio is now approved for subcutaneous use for the treatment of moderatetosevere atopi...
Bayer files for approval of finerenone in heart failure in Japan
Friday, February 14, 2025Bayer today announced the submission of a marketing authorization application to the Ministry of Health Labour and Welfare MHLW in Japan seeking approval of finerenone in adult patients with chronic heart failure with a left ventricular ejection frac...
FDA approves Roche’s Evrysdi tablet as first and only tablet for Spinal Muscular Atrophy (SMA)
Thursday, February 13, 2025Roche announced today that the US Food and Drug Administration FDA has approved a New Drug Application NDA for an Evrysdi risdiplam tablet for people living with spinal muscular atrophy SMA Evrysdi is the only noninvasive diseasemodifying treatment f...
INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer
Thursday, February 13, 2025INmune Bio Inc a clinicalstage immunology and inflammation company continues to advance its Natural Killer NK cell therapy INKmune in a Phase III trial the CaRe PC trial for men with metastatic castrationresistant prostate cancer mCRPC The Company is...
Ellipses In-Licences First in Class Novel Immuno-Oncology Agent With Potential as a Next Generation Checkpoint Inhibitor
Wednesday, February 12, 2025Ellipses Pharma Limited a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model announced today it is to develop a nextgeneration immunooncology drug which could addr...
Linvoseltamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Multiple Myeloma
Wednesday, February 12, 2025Regeneron Pharmaceuticals Inctoday announced that the US Food and Drug Administration FDA has accepted for review the resubmission of the Biologics License Application BLA for linvoseltamab for the treatment of adult patients
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Tuesday, February 11, 2025Boehringer Ingelheim announced today that the FIBRONEERILD trial met its primary endpoint which was the absolute change from baseline in forced vital capacity FVC mL at week versus placebo FVC is a measure of lung function Initial data readouts of t...
NecstGen Partners with Galapagos to Advance Decentralised CAR-T Cell Manufacturing in Europe
Tuesday, February 11, 2025NecstGen a leading Contract Development and Manufacturing Organization CDMO dedicated to Cell and Gene Therapies is proud to announce a strategic collaboration with Galapagos NV a biotechnology company with operations in Europe and the US to support...
